Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Gene therapy for malignant gliomas

J B Alavi¹, S L Eck

¹Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, USA.

Hematology/Oncology Clinics of North America

|July 31, 1998

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Biomarker qualification via public-private partnerships.

Clinical pharmacology and therapeutics·2009

Same author

Gene therapy for high grade gliomas.

Expert opinion on biological therapy·2001

Same author

A simplified one-pot synthesis of 9-[(3-[18F]fluoro-1-hydroxy-2-propoxy)methyl]guanine([18F]FHPG) and 9-(4-[18F]fluoro-3-hydroxymethylbutyl)guanine ([18F]FHBG) for gene therapy.

Nuclear medicine and biology·2001

Same author

Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium.

Neuro-oncology·2001

Same author

Imaging in vivo herpes simplex virus thymidine kinase gene transfer to tumour-bearing rodents using positron emission tomography and.

European journal of nuclear medicine·2001

Same author

Treatment of recurrent or progressive malignant glioma with a recombinant adenovirus expressing human interferon-beta (H5.010CMVhIFN-beta): a phase I trial.

Human gene therapy·2001

Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026

Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026

Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026

Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026

Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026

Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026

See all related articles

Gene therapy offers promising strategies for treating malignant gliomas by targeting tumor biology. These approaches include synthesizing chemotherapy drugs, restoring tumor suppressor genes, blocking angiogenesis, augmenting immune response, and using tumor-selective viruses.

Area of Science:

Oncology
Molecular Biology
Gene Therapy

Background:

Malignant gliomas are a significant therapeutic challenge due to their invasive nature.
Their localized distribution makes them amenable to targeted therapies like gene therapy.
Existing treatments have limitations, necessitating novel therapeutic strategies.

Purpose of the Study:

To explore various gene therapy strategies for malignant gliomas.
To discuss the advantages and limitations of each approach.
To evaluate the potential application of these strategies in treating gliomas.

Main Methods:

Gene transfer for chemotherapy drug synthesis.
Introduction of genes to restore tumor suppressor functions.
Gene therapy to inhibit tumor angiogenesis.

Related Experiment Videos

Augmentation of immune response via cytokine production.

Oncolytic virotherapy for selective tumor cell destruction.

Main Results:

Gene therapy can be designed to block DNA synthesis in rapidly dividing glioma cells.
Restoring tumor suppressor genes or inhibiting angiogenesis can impede tumor growth.
Local cytokine production can enhance the anti-glioma immune response.
Engineered viruses show potential for selective glioma cell lysis.
Each strategy presents unique advantages and limitations for clinical application.

Conclusions:

Gene therapy offers a versatile platform for targeting malignant gliomas.
Multiple gene-based approaches demonstrate potential for treating these lethal brain tumors.
Further research is needed to optimize and translate these strategies into effective clinical treatments.